Binet Staging System for CLL

Classifies CLL by the number of involved lymphoid regions and by whether anemia or thrombocytopenia is present.

Areas of lymphadenopathy
< 3+1≥ 3+2
Anemia (Hgb < 10 g/dL)
No0Yes+3
Thrombocytopenia (plts < 100,000/mm^3)
No0Yes+3

Indications for Use

Stratifies newly diagnosed CLL into A, B, C using hemoglobin, platelets, and number of involved lymphoid areas.

  • Indications: Apply at diagnosis in all CLL patients to define tumor burden and baseline prognosis 1.
  • Clinical utility: Guides watch‑and‑wait for asymptomatic A/B disease and identifies C disease as treatment‑requiring due to cytopenias 1.

Insights & Cautions

Starts with grouping patients into A (favorable), B (intermediate), and C (advanced), based on cytopenias and number of involved lymphoid areas.

  • Strengths: Simple bedside tool; reliably separates broad prognostic groups 1 [Level III evidence].
  • Cautions: Limited precision in the era of targeted agents; does not account for IGHV, TP53, or cytogenetics, which strongly influence outcomes 2 [Level II evidence].
  • Implication: Useful for treatment indication, but insufficient alone for prognostication.